News Release

July 31, 2020
JCR Pharmaceuticals Co., Ltd.

Translation

Start of Discussions with AstraZeneca
Regarding Domestic Production of COVID-19 Vaccine Drug Substance

JCR Pharmaceuticals Co., Ltd. (TSE 4552; Chairman and President: Shin Ashida; "JCR") announced the start of discussions with AstraZeneca K.K. (Headquarters: Kita-ku, Osaka, "AstraZeneca") regarding the production of drug substance in Japan for the adenovirus vector-based COVID-19vaccine, known as AZD1222.

The vaccine was co-invented by the University of Oxford and its spin-out company, Vaccitech, and licensed by AstraZeneca. On June 26, 2020 AstraZeneca began detailed discussion with the Japanese government toward the introduction of the vaccine in Japan.

As a pharmaceutical company with manufacturing capabilities for biopharmaceuticals, we will accelerate manufacturing of drug substance of this vaccine with support of our research members engaging in the development of JCR's gene therapy technology.
We will make maximum effort to ensure a stable supply of this vaccine in Japan in order to contribute to a potential solution to the coronavirus pandemic.

[About JCR Pharmaceuticals]
JCR is a specialty pharma company engaged in the research, development, manufacturing and marketing of biopharmaceuticals and regenerative medicine with a focus on rare diseases. Its philosophy, "Contributing towards people's healthcare through pharmaceutical products" drives JCR to create innovative pharmaceutical products as value-added treatment options for the under-served patient populations.

[Cautionary Statement Regarding Forward-Looking Statements]
This document contains forward-looking statements that are subject to known and unknown risks and uncertainties, many of which are outside our control. Forward-looking statements often contain words such as "believe," "estimate," "anticipate," "intend," "plan," "will," "would," "target" and similar references to future periods. All forward-looking statements regarding our plans, outlook, strategy and future business, financial performance and financial condition are based on judgments derived from the information available to us at this time. Factors or events that could cause our actual results to be materially different from those expressed in our forward-looking statements include, but not limited to, a deterioration of economic conditions, a change in the legal or governmental system, a delay in launching a new product, impact on competitors' pricing and product strategies, a decline in marketing capabilities relating to our products, manufacturing difficulties or delays, an infringement of our intellectual property rights , an adverse court decision in a significant lawsuit and regulatory actions.

This document involves information on pharmaceutical products (including those under development). However, it is not intended for advertising or providing medical advice. Furthermore, it is intended to provide information on our company and businesses and not to solicit investment in securities we issue.
Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the factors that could cause actual results to differ materially, even if new information becomes available in the future.

Investors & Media:
JCR Pharmaceuticals Co., Ltd.
Corporate Communications
ir-info@jcrpharm.co.jp

END
###